<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105715</url>
  </required_header>
  <id_info>
    <org_study_id>UAMS 112170</org_study_id>
    <nct_id>NCT01105715</nct_id>
  </id_info>
  <brief_title>Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis</brief_title>
  <acronym>cLDL in RA</acronym>
  <official_title>cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that cLDL levels are elevated in RA patients and represents an&#xD;
      important mechanism for accelerated atherosclerosis leading to excess cardiovascular disease&#xD;
      (CVD) in rheumatoid arthritis (RA) patients. The purpose of this study is to improve&#xD;
      understanding of the reasons for increased cardiovascular diseases (such as heart attack and&#xD;
      stroke) seen in patients with rheumatoid arthritis (RA, an arthritis that causes inflammation&#xD;
      and destruction of joints). Specifically, the study plans to determine whether a particular&#xD;
      type of change in proteins in LDL cholesterol (&quot;bad cholesterol&quot;) known as carbamylation is&#xD;
      an important risk factor for cardiovascular diseases in RA patients. The study will utilize a&#xD;
      case-control study design. A total of 120 subjects (males and females between the ages of 18&#xD;
      and 80) may be enrolled in order to ensure that 100 subjects (50 RA case subjects and 50 age&#xD;
      and sex matched controls) complete the study. Procedures will consist of a single visit for&#xD;
      each subject during which a screening evaluation, an enrollment evaluation, and a single&#xD;
      blood draw will be performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis (RA) Case Subjects</arm_group_label>
    <description>Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA&#xD;
Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of &gt;10&#xD;
Have &gt; or = 3 swollen joints</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Subjects</arm_group_label>
    <description>Age, sex, and 5-year age categories matched to cases&#xD;
No historical diagnosis of RA and other primary autoimmune or inflammatory disorders</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      If a subject consents, any blood samples remaining after the tests planned for this study&#xD;
      will be stored indefinitely for potential future new studies. Any future new studies using&#xD;
      these blood samples will require prior approval by the UAMS Institutional Review Board (IRB).&#xD;
      A subject may request destruction of the stored samples at any time.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the UAMS Rheumatology Clinic at the UAMS Outpatient Center,&#xD;
        Little Rock, other UAMS outpatient clinics, or through advertisement at the UAMS campus&#xD;
        and/or the community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Cases:&#xD;
&#xD;
          -  Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA&#xD;
&#xD;
          -  Have currently active disease as assessed by Clinical Disease Activity Index&#xD;
             (CDAI)score (a validated composite RA activity index) of &gt; 10&#xD;
&#xD;
          -  Have â‰¥ 3 swollen joints&#xD;
&#xD;
        For Controls:&#xD;
&#xD;
          -  Control subjects will be age, sex, and 5-year age categories matched to cases&#xD;
&#xD;
          -  No historical diagnosis of RA and other primary autoimmune or inflammatory disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For both cases and controls:&#xD;
&#xD;
        Renal failure (estimated GFR &lt; 60 ml/min) documented within 3 months of study enrollment&#xD;
        (from either subject's self-report or review of available medical records)&#xD;
&#xD;
          -  Known clinical history of CVD&#xD;
&#xD;
          -  Current cancer (other than skin)&#xD;
&#xD;
          -  Current or recent (within past 2 weeks) infection&#xD;
&#xD;
          -  Individuals taking lipid-lowering medications&#xD;
&#xD;
          -  Any other condition the PI staff feels will jeopardize the health and welfare of the&#xD;
             participants&#xD;
&#xD;
          -  Rheumatoid vasculitis (for cases only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>cLDL</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

